natgillin/translations-raw huggingface dataset:
Patients should be informed that Esbriet is known to be associated with photosensitivity reactions and that preventative measures have to be taken.
Bolnike je treba obvestiti, da se pri jemanju zdravila Esbriet lahko pojavljajo reakcije preobčutljivosti na svetlobo in da je treba izvesti ustrezne zaščitne ukrepe.
Patients should be informed that fatigue has been reported during treatment with Exviera in combination with ombitasvir/paritaprevir/ritonavir and ribavirin (see section 4.8).
Bolnikom je treba povedati, da je bila med zdravljenjem z zdravilom Exviera v kombinaciji z ombitasvirjem/paritaprevirjem/ritonavirjem in ribavirinom opisana utrujenost (glejte poglavje 4.8).
Patients should be informed that fatigue, dizziness and somnolence have been reported during treatment with the components of Odefsey (see section 4.8).
Bolnike je treba opozoriti, da se lahko v času zdravljenja z učinkovinami zdravila Odefsey pojavijo utrujenost, omotičnost in somnolenca (glejte poglavje 4.8).
Patients should be informed that heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergics such as oxybutynin are used in a hot environment.
Bolnike je treba informirati, da lahko pride do vročinske kapi (zvišana telesna temperatura in vročinska kap zaradi zmanjšanega znojenja) pri uporabi antiholinergikov kot je oksibutinin v zelo vročem okolju.
Patients should be informed that heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergics such as oxybutynin are used in a hot environment.
Bolnike je treba opozoriti, da lahko pri uporabi antiholinergikov, kot je oksibutinin, v vročem okolju pride do prostracije (zvišana telesna temperatura in toplotni udar zaradi zmanjšanega potenja).
Patients should be informed that hepatic reactions are a major toxicity of nevirapine requiring close monitoring during the first 18 weeks.
Bolnikom je treba povedati, da so jetrne reakcije pomemben toksični pojav ob nevirapinu, zaradi katerega je prvih 18 tednov treba skrbno spremljati zdravljenje.
Patients should be informed that saquinavir is not a cure for HIV infection and that they may continue to acquire illnesses associated with advanced HIV infection, including opportunistic infections.
Bolnike je treba obvestiti, da sakvinavir ni zdravilo za ozdravitev okužbe s HIV, in da lahko še vedno zbolijo za obolenji, povezanimi z napredovalo okužbo s HIV, vključno z oportunističnimi okužbami.
Patients should be informed that they have received Refludan.
Bolniki morajo biti obveščeni, da so dobili Refludan.
Patients should be informed to seek urgent medical care in case that priapism has not been resolved within 3-4 hours.
Bolnike je treba poučiti, da poiščejo zdravniško pomoč, če priapizem ne izveni v 2-3 urah.
Patients should be instructed and trained appropriately.
Bolniku je treba dati ustrezna navodila in ga izuriti.
Patients should be instructed in how to recognise symptoms of serious allergic reactions.
Bolnikom je treba dati navodila za prepoznavanje simptomov resnih alergijskih reakcij.
Patients should be instructed not to inject a double dose to make up for the forgotten dose.
Bolnikom morate naročiti, naj si ne injicirajo dvojnega odmerka, da bi nadomestili pozabljeni odmerek.
Patients should be instructed not to swallow NEVANAC.
Bolnike morate poučiti, naj zdravila ne pogoltnejo.
Patients should be instructed on how to administer the product correctly.
Bolnike je treba poučiti o tem, kako pravilno vzamejo zdravilo.
Patients should be instructed that any solution left in the bottle 45 days after opening should be disposed of in accordance with local requirements or returned to the pharmacy.
Bolniki morajo biti opozorjeni, da je treba raztopino zdravila, ki ostane v plastenki po preteku 45 dni od odprtja plastenke, zavreči v skladu z lokalnimi predpisi ali vrniti nazaj v lekarno.
Patients should be instructed that if they experience dizziness they should avoid potentially hazardous tasks such as driving or operating machines.
Bolnikom je treba naročiti, naj v primeru, da se jim pojavi omotica, ne opravljajo potencialno nevarnih dejavnosti, kot sta vožnja in upravljanje s stroji.
Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving or operating machinery.
Bolnikom je treba naročiti, naj se v primeru teh simptomov izogibajo potencialno nevarnim opravilom, kakršna sta vožnja ali upravljanje s stroji.
Patients should be instructed to consult a doctor if:
Bolnikom je treba naročiti, naj se posvetujejo z zdravnikom:
Patients should be instructed to consult their healthcare professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discoloured faeces.
Bolnikom je treba naročiti, naj se takoj posvetujejo z zdravnikom, če se pri njih pojavi utrujenost, splošna oslabelost, pomanjkanje apetita, navzea in bruhanje, zlatenica ali svetlo blato.
Patients should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment.
Bolnikom morate naročiti, naj se nemudoma posvetujejo z zdravnikom, če se pojavi kakršenkoli simptom okužbe, da bodo deležni hitre ocene stanja in ustreznega zdravljenja.
Patients should be instructed to discard the remaining volume in the solvent vials.
Bolnike je treba podučiti, da zavržejo preostalo količino vehikla v viali.
Patients should be instructed to inform their nurse or physician immediately if they experience any of the above signs or symptoms.
Bolnikom je treba naročiti, naj medicinski sestri ali zdravniku nemudoma povedo, če se pri njih pojavi kateri od naštetih znakov ali simptomov.
Patients should be instructed to inject the full amount of Simponi according to the comprehensive instructions for administration provided in the package leaflet.
Bolnikom je treba naročiti, naj si injicirajo celotno količino zdravila Simponi v skladu z obsežnimi navodili za injiciranje, ki so na voljo v navodilu za uporabo.
Patients should be instructed to notify these signs immediately to their physicians if they occur, notably if patients had a good tolerance to metformin before.
Bolnikom naročite, da ob pojavu navedenih znakov nemudoma obvestijo svojega zdravnika, zlasti, če so bolniki pred tem dobro prenašali metformin.
Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with Humira.
Bolnikom je treba naročiti, naj poiščejo zdravniško pomoč, če med zdravljenjem z zdravilom Humira ali po njem doživijo znake ali simptome, ki nakazujejo tuberkulozno okužbo (npr. trdovraten kašelj, hujšanje/izgubljanje teže, nekoliko zvišano telesno temperaturo).
Patients should be instructed to seek medical advice if signs/symptoms suggestive of photosensitivity occur during or after therapy with porfimer.
Bolnike je treba poučiti, da se v primeru, da se med ali po zdravljenju s porfirini pojavijo fotosenzitivne reakcije, posvetujejo z zdravnikom.
Patients should be instructed to seek medical attention if signs or symptoms of neurotoxicity develop, or if oral dexamethasone is not well tolerated.
Bolnike morate poučiti, naj takoj poiščejo zdravniško pomoč, če opazijo znake ali simptome nevrotoksičnosti ali če peroralno zaužitega deksametazona ne prenašajo dobro.
Patients should be instructed to seek medical attention promptly if these occur.
Bolnikom moramo naročiti, da morajo ob njihovem pojavu nemudoma poiskati zdravniško pomoč.
Patients should be instructed to stay well hydrated (e.g.
Bolnikom je treba naročiti, naj poskrbijo za dobro hidracijo (npr.
Patients should be instructed to stop the medicinal product and seek medical attention if these symptoms develop while taking eluxadoline (see section 4.8).
Bolnikom je treba naročiti, naj prenehajo jemati zdravilo in poiščejo zdravniško pomoč, če se med zdravljenjem z eluksadolinom pojavijo ti simptomi (glejte poglavje 4.8).
Patients should be instructed to stop the medicinal product and seek medical attention if they develop severe constipation for more than 4 days (see section 4.4).
Bolnikom je treba naročiti, naj prenehajo jemati zdravilo in poiščejo zdravniško pomoč, če se pojavi huda zaprtost, ki traja dlje kot 4 dni (glejte poglavje 4.4).
Patients should be instructed to stop the treatment and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain (e.g. acute epigastric or biliary [i.e., right upper quadrant] pain) that may radiate to the back or shoulder, with or without nausea and vomiting.
Bolnikom je treba naročiti, naj prenehajo jemati zdravilo in poiščejo zdravniško pomoč, če se pojavijo simptomi, ki nakazujejo spazem Oddijevega sfinktra, kot je akutno poslabšanje bolečine v trebuhu (npr. akutna epigastrična ali biliarna bolečina [tj. v zgornjem desnem kvadrantu]), ki lahko seva v hrbet ali rame, z navzeo in bruhanjem ali brez njiju.
Patients should be instructed to swallow the tablet(s) whole with a liquid such as water.
Bolnike je treba poučiti naj tableto pogoltnejo celo s kozarcem tekočine (na primer vode).
Patients should be instructed to swallow the tablets whole (e.g. patients should not chew, break or dissolve the tablet).
Bolnike je treba poučiti, naj tablete pogoltnejo cele (ne smejo jih žvečiti, zlomiti ali raztopiti).
Patients should be instructed to swallow the tablets whole (i.e., patients should not chew, break or dissolve the tablets).
Bolnikom je treba naročiti, naj tablete pogoltnejo cele (t.j., bolniki tablet ne smejo žvečiti, zdrobiti ali raztopiti).
Patients should be instructed to use a sunblock daily, to wear clothing that protects against sun exposure, and to avoid other medications known to cause photosensitivity.
Bolnikom je treba naročiti, naj vsak dan uporabljajo kremo za sončenje, nosijo oblačila, ki ščitijo pred izpostavljenostjo soncu, in se izogibajo drugim zdravilom, za katera je znano, da povzročajo preobčutljivost na svetlobo.
Patients should be instructed to wash their hands with soap and water, immediately after applying Picato and between topical applications if two different areas require different strengths.
Bolnikom naročite, naj si po nanosu zdravila Picato in med lokalnimi nanosi, če je treba na dveh različnih mestih uporabiti različne jakosti gela, nemudoma umijejo roke z milom in vodo.
Patients should be made aware of the symptoms of second-degree or higher AV block (e.g. slow or irregular pulse, feeling of lightheaded and fainting) and of the symptoms of atrial fibrillation and flutter (e.g. palpitations, rapid or irregular pulse, shortness of breath).
Bolniki morajo biti seznanjeni s simptomi atrioventrikularnega bloka druge ali višje stopnje (npr. počasen ali nepravilen srčni utrip, občutek lahke glave in omedlevica) ter s simptomi atrijske fibrilacije in undulacije (npr. palpitacije, hiter ali nepravilen srčni utrip, zasoplost).
Patients should be made aware of this.
Bolnice je treba na to opozoriti.
Patients should be made aware that Aerivio Spiromax must be used daily for optimum benefit, even when asymptomatic.
Bolnikom je treba pojasniti, da morajo za najboljši učinek zdravilo Airexar Spiromax uporabljati vsak dan, tudi kadar nimajo simptomov.
Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8).
Sprememba farmacevtske oblike zdravila ali režima odmerjanja lahko poteka le pod strogim nadzorom zdravnika specialista za zdravljenje bolnikov s presadki (glejte poglavji 4.2 in 4.8).
Patients should be monitored after the injection to check for infection or raised eye pressure.
Bolnike je treba po injiciranju nadzorovati, da se odkrije morebitna okužba ali povišan očesni tlak.
Patients should be monitored as clinically appropriate.
Bolnike je treba kontrolirati, kot je klinično primerno.
Patients should be monitored carefully (see section 4.4).
Bolnike je treba natančno nadzorovati (glejte poglavje 4.4).
Patients should be monitored carefully for signs of relapse during the first one to two months of treatment.
Bolnike je v prvem enem do dveh mesecih zdravljenja potrebno skrbno spremljati za znake relapsa.
Patients should be monitored closely to ensure that the lowest approved dose of erythropoiesis- stimulating agent (ESA) is used to provide adequate control of the symptoms of anaemia.
Bolnike je treba skrbno spremljati, da se zagotovi uporaba najmanjšega odobrenega odmerka zdravila za stimulacijo eritropoeze (ESA - erythropoiesis stimulating agent) za doseganje ustreznega nadzora simptomov anemije.
Patients should be monitored closely to ensure that the lowest approved dose of NeoRecormon is used to provide adequate control of the symptoms of anaemia.
Bolnike moramo pozorno spremljati, da lahko simptome anemije ustrezno nadzorujemo s čim manjšim odobrenim odmerkom zdravila NeoRecormon.
Patients should be monitored closely to ensure that the lowest approved dose of Nespo is used to provide adequate control of the symptoms of anaemia.
Bolnike morate natančno kontrolirati in tako zagotoviti uporabo najmanjšega odobrenega odmerka Nespa, ki je potreben za ustrezno obvladanje simptomov anemije
Patients should be monitored closely to ensure that the lowest approved dose of Nespo is used to provide adequate control of the symptoms of anaemia.
Bolnike morate natančno kontrolirati in tako zagotoviti uporabo najmanjšega odobrenega odmerka Nespa, ki je potreben za ustrezno obvladanje simptomov anemije.
Patients should be monitored closely to ensure that the lowest approved dose of Retacrit is used to provide adequate control of the symptoms of anaemia.
Bolnike morate pozorno nadzorovati, da bi zagotovili uporabo najnižjega odobrenega odmerka zdravila Retacrit za primeren nadzor simptomov anemije.
Patients should be monitored closely to ensure that the lowest approved effective dose of Abseamed is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.45 mmol/l).
Bolnike je treba skrbno spremljati, da se zagotovi uporaba najmanjšega odobrenega učinkovitega odmerka zdravila Abseamed za doseganje ustreznega nadzora simptomov anemije ob hkratnem ohranjanju koncentracije hemoglobina pod ali pri 12 g/dl (7,45 mmol/l).
Patients should be monitored closely to ensure that the lowest approved effective dose of Aranesp is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.5 mmol/l).
Bolnike je treba skrbno nadzirati, da bi zagotovili uporabo najmanjšega odobrenega učinkovitega odmerka zdravila Aranesp, potrebnega za ustrezno obvladanje simptomov anemije ob hkratnem vzdrževanju koncentracije hemoglobina pod ali na 12 g/dl (7,5 mmol/l).
Patients should be monitored closely to ensure that the lowest approved effective dose of Binocrit is used to provide adequate control of anaemia and of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.45 mmol/l).
Bolnike je treba skrbno spremljati, da se zagotovi uporaba najmanjšega odobrenega učinkovitega odmerka zdravila Binocrit za doseganje ustreznega nadzora anemije in simptomov anemije ob hkratnem ohranjanju koncentracije hemoglobina pod ali pri 12 g/dl (7,45 mmol/l).
Patients should be monitored closely to ensure that the lowest approved effective dose of Epoetin alfa HEXAL is used to provide adequate control of anaemia and of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.45 mmol/l).
Bolnike je treba skrbno spremljati, da se zagotovi uporaba najmanjšega odobrenega učinkovitega odmerka zdravila Epoetin alfa HEXAL za doseganje ustreznega nadzora anemije in simptomov anemije ob hkratnem ohranjanju koncentracije hemoglobina pod ali pri 12 g/dl (7,45 mmol/l).
Patients should be monitored closely to ensure that the lowest approved effective dose of Retacrit is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12g/dl (7.5 mmol/l).
Bolnike morate skrbno nadzorovati, da bi zagotovili uporabo najnižjega odobrenega učinkovitega odmerka zdravila Retacrit za primeren nadzor simptomov anemije, pri čemer naj koncentracija hemoglobina ostane pod ali pri 12g/dl (7,5 mmol/l).
Patients should be monitored closely to ensure that the lowest approved effective dose of Silapo is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12g/dl (7.5 mmol/l).
Bolnike morate skrbno nadzorovati, da bi zagotovili uporabo najnižjega odobrenega učinkovitega odmerka zdravila Silapo za primeren nadzor simptomov anemije, pri čemer naj koncentracija hemoglobina ostane pod ali pri 12g/dl (7,5 mmol/l).
Patients should be monitored during and after the infusion for certain side effects and they should have full blood counts checked before every dose of Adcetris.
Bolnike je treba med infundiranjem in po njem spremljati glede pojava določenih neželenih učinkov, pred vsakim odmerkom zdravila Adcetris pa je treba pridobiti popolno krvno sliko bolnika.
Patients should be monitored during micafungin treatment for anaphylactic/anaphylactoid reactions, worsening of liver function, worsening of renal function, haemolysis, exfoliative cutaneous reactions, and concomitant drug therapy toxicity and adequate measures (discontinuation or evaluation for the risk/benefit of continuing micafungin therapy and treatment of adverse reactions) should be undertaken when such conditions occur.
V času zdravljenja z mikafunginom je bolnike potrebno skrbno spremljati glede anafilaktičnih/anafilaktoidnih reakcij, poslabšanja delovanja jeter, poslabšanja delovanja ledvic, hemolize, eksfoliativnih kožnih reakcij ter toksičnosti sočasnega zdravljenja z zdravili in izvesti ustrezne ukrepe (ukinitev ali oceno za tveganje / koristi nadaljevanja zdravljenja z mikafunginom in zdravljenje neželenih učinkov), če se pojavijo takšna stanja.
Patients should be monitored following medical withdrawal because of the potential for relapse.
Zaradi morebitnega relapsa je treba spremljati bolnike po medicinski odtegnitvi.
Patients should be monitored for
je treba uporabljati tudi zanesljivo
Patients should be monitored for
Pri bolnikih je potrebno nadzirati
Patients should be monitored for hepatotoxicity and managed as recommended in sections 4.2 and 4.4.
Zaradi hepatotoksičnosti je treba bolnike spremljati in obravnavati, kot je priporočeno v poglavjih 4.2 in 4.4.
Patients should be monitored for liver function, particularly in case of pre-existing liver disorder or concomitant use of medication susceptible to induce liver dysfunction (see section 4.8).
Pri bolnikih je treba spremljati delovanje jeter, posebno v primeru obstoječe bolezni jeter ali sočasnega jemanja zdravil, ki lahko povzročijo disfunkcijo jeter (glejte poglavje 4.8).
Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to ≥ 1,500 cells/mm3 and platelet count returns to ≥ 100,000 cells/mm3.
Pri bolnikih moramo biti med zdravljenjem pozorni na morebiten pojav mielosupresije, pemetrekseda pa bolnikom ne smemo dajati, dokler se absolutno število nevtrofilcev (ANC) ne povrne na ≥ 1500 celic/mm3 ter število trombocitov na ≥ 100.000 celic/mm3.
Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to ≥ 1500 cells/mm3 and platelet count returns to ≥ 100,000 cells/mm3.
Pri bolnikih je med zdravljenjem potrebno biti pozoren na morebiten pojav mielosupresije, pemetrekseda pa bolnikom ne smemo dajati, dokler se absolutno število nevtrofilcev (ANC) ne povrne na ≥ 1500 celic/mm3 ter število trombocitov na ≥ 100.000 celic/mm3.
Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to ≥ 1500 cells/mm3 and platelet count returns to ≥ 100,000 cells/mm3.
Pri bolnikih moramo biti med zdravljenjem pozorni na morebiten pojav mielosupresije, pemetrekseda pa bolnikom ne smemo dajati, dokler se absolutno število nevtrofilcev (ANC) ne povrne na  1500 celic/mm3 ter število trombocitov na  100.000 celic/mm3.
Patients should be monitored for new or worsening abdominal pain, that may radiate to the back or shoulder , with or without nausea and vomiting.
Bolnike je treba opazovati zaradi možnosti nove ali poslabšane bolečine v trebuhu, ki lahko seva v hrbet ali rame, z navzeo in bruhanjem ali brez njiju.
Patients should be monitored for pulmonary symptoms indicative of ILD (e.g. cough, fever, dyspnoea and/or hypoxia), and topotecan should be discontinued if a new diagnosis of ILD is confirmed.
Bolnike je treba kontrolirati glede pljučnih simptomov, ki kažejo na IBP (npr. kašelj, zvišana telesna temperatura, dispneja in/ali hipoksija); če je diagnoza IBP potrjena, je treba zdravljenje s topotekanom prekiniti.
Patients should be monitored for pulmonary symptoms indicative of pneumonitis.
Bolnike je treba opazovati glede pojavljanja pljučnih simptomov, ki bi lahko kazali na pnevmonitis.
Patients should be monitored for QT prolongation and managed as recommended in sections 4.2 and 4.4.
Pri bolnikih je treba spremljati trajanje intervala QT in v primeru podaljšanja ukrepati v skladu s priporočili v poglavjih 4.2 in 4.4.
Patients should be monitored for seizure control.
Bolnike je treba spremljati glede možnosti valprojska kislina/emtricitabin Interakcij niso preučevali. epileptičnih napadov.
Patients should be monitored for severe infections including sepsis and septic shock.
Bolnike je treba spremljati glede pojava hudih okužb, vključno s sepso in septičnim šokom.
Patients should be monitored for signs and symptoms of hypophysitis (including hypopituitarism and secondary adrenal insufficiency) and other causes excluded.
Bolnike je treba spremljati glede znakov in simptomov hipofizitisa (vključno s hipopituitarizmom in sekundarno adrenalno insuficienco) in izključiti druge vzroke.
Patients should be monitored for signs of busulfan toxicity when itraconazole is used as an antifungal prophylaxis with intravenous busulfan.
Ko se itrakonazol uporablja kot profilaksa proti glivicam skupaj z intravensko uporabljenim busulfanom, je pri bolnikih treba spremljati znake toksičnosti busulfana.
Patients should be monitored for signs of busulfan toxicity when itraconazole is used as an antifungal prophylaxis with intravenous busulfan.
Ko se itrakonazol uporablja preventivno proti glivicam skupaj z intravensko uporabljenim busulfanom, je pri bolnikih treba spremljati znake toksičnosti busulfana.
Patients should be monitored for signs of hepatic injury and monthly monitoring of ALT and AST is recommended.
Bolnike je treba nadzirati glede znakov okvare jeter in je priporočljivo mesečno določanje vrednosti ALT in AST.
Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.
Pri bolnikih je potrebno nadzirati odtegnitvene znake in povišati odmerek metadona, kolikor je to potrebno za ublažitev odtegnitvenih simptomov.
Patients should be monitored for symptoms of congestive heart failure during therapy and during the follow up period.
Pri bolnicah je med terapijo in v obdobju spremljanja po terapiji treba opazovati morebitne simptome zastojnega srčnega popuščanja.
Patients should be monitored for symptoms or signs of decreased peripheral blood counts (see section 4.8).
Bolnike je treba opazovati za pojav simptomov ali znakov zmanjšanja perifernih krvnih vrednosti (glejte poglavje 4.8).
Patients should be monitored for the development of factor IX inhibitors.
Bolnike moramo spremljati zaradi morebitnega razvoja inhibitorjev faktorja IX.